Immunovant, inc. (HSAC)
CashFlow / Quarterly
Dec'19Sep'19Jun'19Mar'19
Cash flows from operating activities
Net loss

-46,144

125

182

-0

Changes in operating assets and liabilities:
Net cash used in operating activities

-29,775

-301

-230

-0

Cash flows from financing activities
Payment of deferred offering costs

2,511

0

405

176

Net cash provided by financing activities

29,878

0

116,994

-176

Net Change in Cash

-

-301

1,764

-177